BioCentury
ARTICLE | Company News

MorphoSys, GlaxoSmithKline deal

June 10, 2013 7:00 AM UTC

MorphoSys granted GlaxoSmithKline exclusive, worldwide rights to develop and commercialize its MOR103 program. MorphoSys will receive €22.5 million ($29.3 million) up front and is eligible for up to ...